Last reviewed · How we verify
Chitin microparticles by nasal route
Chitin microparticles by nasal route is a Small molecule drug developed by CMP Therapeutics Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | Chitin microparticles by nasal route |
|---|---|
| Sponsor | CMP Therapeutics Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chitin microparticles by nasal route CI brief — competitive landscape report
- Chitin microparticles by nasal route updates RSS · CI watch RSS
- CMP Therapeutics Ltd portfolio CI
Frequently asked questions about Chitin microparticles by nasal route
What is Chitin microparticles by nasal route?
Chitin microparticles by nasal route is a Small molecule drug developed by CMP Therapeutics Ltd.
Who makes Chitin microparticles by nasal route?
Chitin microparticles by nasal route is developed by CMP Therapeutics Ltd (see full CMP Therapeutics Ltd pipeline at /company/cmp-therapeutics-ltd).
What development phase is Chitin microparticles by nasal route in?
Chitin microparticles by nasal route is in Phase 1.
Related
- Manufacturer: CMP Therapeutics Ltd — full pipeline